Research ArticleFibrosis

The αvβ1 integrin plays a critical in vivo role in tissue fibrosis

See allHide authors and affiliations

Science Translational Medicine  20 May 2015:
Vol. 7, Issue 288, pp. 288ra79
DOI: 10.1126/scitranslmed.aaa5094

Integrating integrin inhibition

Integrins are a family of cell surface receptors that form cell-cell and cell–extracellular matrix contacts and, as such, are key targets in treating fibrotic disease. However, promiscuous pairing has limited our understanding of the contribution of individual integrin heterodimers. Now, Reed et al. have developed a specific small-molecule inhibitor of the integrin αvβ1, which is highly expressed on activated fibroblasts. This inhibitor decreased the severity of disease in mouse models of lung and liver fibrosis, in part through downstream effects on transforming growth factor–β. These data suggest that αvβ1 may be a viable target for fibrosis therapy.


Integrins are transmembrane heterodimeric receptors that contribute to diverse biological functions and play critical roles in many human diseases. Studies using integrin subunit knockout mice and inhibitory antibodies have identified important roles for nearly every integrin heterodimer and led to the development of a number of potentially useful therapeutics. One notable exception is the αvβ1 integrin. αv and β1 subunits are individually present in numerous dimer pairs, making it challenging to infer specific roles for αvβ1 by genetic inactivation of individual subunits, and αvβ1 complex–specific blocking antibodies do not yet exist. We therefore developed a potent and highly specific small-molecule inhibitor of αvβ1 to probe the function of this understudied integrin. We found that αvβ1, which is highly expressed on activated fibroblasts, directly binds to the latency-associated peptide of transforming growth factor–β1 (TGFβ1) and mediates TGFβ1 activation. Therapeutic delivery of this αvβ1 inhibitor attenuated bleomycin-induced pulmonary fibrosis and carbon tetrachloride–induced liver fibrosis, suggesting that drugs based on this lead compound could be broadly useful for treatment of diseases characterized by excessive tissue fibrosis.


Integrins are present in nearly all multicellular organisms and play a conserved role in mediating cell adhesion to fixed extracellular ligands and in the maintenance of tissue integrity (1). In invertebrates, a surprisingly small number of integrin heterodimers mediate these diverse functions (2, 3). Much has been learned about the critical in vivo functions of most members of the integrin family through the use of mice with global or conditional inactivating mutations of individual subunits (4, 5) and through the use of heterodimer-specific blocking monoclonal antibodies (6, 7). One major exception is the αvβ1 integrin. This integrin, first identified biochemically more than two decades ago (8), is composed of α and β subunits that are both present in multiple heterodimers (5 in the case of αv and 12 in the case of β1) (1), which has made it difficult to generate heterodimer-specific antibodies or to infer function from gene knockout studies. As a result, this integrin has been largely ignored.

We and others have shown that two members of the integrin family, αvβ6 and αvβ8, have as their principal ligands latency-associated peptides (LAPs) of the growth factors TGFβ1-3 (transforming growth factor–β1-3) (911) and that these integrins play major roles in activation of latent forms of this growth factor that are stored in the extracellular matrix in most healthy adult tissues. In mice, inactivation of both of these integrins recapitulates all of the developmental phenotypes of loss of TGFβ1 and TGFβ3 (12). Inhibitors of each of these integrins have identified important and distinct roles for each in multiple disease models and have provided new options for therapeutically targeting TGFβ in specific contexts, thereby avoiding potentially undesirable side effects of globally inhibiting this pleiotropic growth factor (9, 1316).

However, in contrast to development, it is clear that there are a number of important pathologic circumstances in adults where inhibition of TGFβ is therapeutically effective, but inhibition of αvβ6 and αvβ8 is not. One of these is hepatic fibrosis (17). We recently used cre-mediated deletion of the integrin αv subunit in activated fibroblasts to demonstrate that loss of all αv integrins from these cells protects mice from fibrosis in multiple organs, including the liver, and that this effect was associated with reduced tissue TGFβ signaling (17). Tissue fibroblasts can express four αv-containing integrins, αvβ1, αvβ3, αvβ5, and αvβ8. We found that individual deletion of αvβ3, αvβ5, or αvβ8 integrin either globally or conditionally in activated fibroblasts (in the case of αvβ8 integrin) had no effect on organ fibrosis but were unable to examine any possible contributions of the αvβ1 integrin because of the lack of suitable experimental tools. Our previous results could thus have been explained either by redundancy of αv integrins (the interpretation we favored) or by a specific role for fibroblast αvβ1 in driving fibrosis.

To begin to identify important functions for the αvβ1 integrin, we used information from the solved crystal structure of other αv and β1 integrins (18, 19) and from the design of other small-molecule inhibitors targeting integrins (20), to develop a potent and specific small-molecule inhibitor of the αvβ1 integrin. We then used this inhibitor to demonstrate a previously unknown role for this integrin in activating the growth factor TGFβ and in driving tissue fibrosis in the lung and liver.


Design and synthesis of an αvβ1 integrin–specific inhibitor

Starting with a base compound that specifically binds to the αv subunit in αvβ3 integrin, we looked to impart β1 subunit–binding specificity through addition of a sulfonamidoproline moiety we had previously shown to bind to the β1 subunit in α2β1 integrin (Fig. 1A, blue shading), which occupies a hydrophobic pocket in the β1 chain (20).

Fig. 1. αvβ1 integrin inhibitor design and demonstration of potency and specificity.

(A) Design principle of αvβ1 integrin inhibitor by combining a positively charged guanidine moiety in αvβ3 integrin inhibitor (blue shading) and a sulfonamidoproline moiety in α2β1 integrin inhibitor (green shading). (B) Structures of αvβ1 integrin–specific inhibitor c8. (C) Docking model of αvβ1 integrin inhibitor c8 bound to αvβ1 integrin, where α and β subunits are, respectively, in green and blue. The model predicted that a linker length of n = 3 or 4 would have the highest affinity. (D) Dose-dependent cell adhesion assay of c8 against all αv and related integrins. (E) Curve-fitted IC50 of c8 against RGD (arginine–glycine–aspartic acid)–binding integrins in cell adhesion assay. Data represent means ± SEM; n = 3 (three experimental replicates).

Because cocrystal structures are available for the ligand-binding regions of the αvβ3 and α5β1 integrins (18, 19), we were able to construct a computational model of the αvβ1 integrin to further guide our inhibitor design (Fig. 1C). We then synthesized a small set of compounds, including the αv-binding base compound and the β1-binding sulfonamidoproline moiety separated by amide linkers of various lengths, and found outstanding geometric and electrostatic complementarity when these were docked to our model of the αvβ1 integrin. Potency and specificity of each compound were tested by performing cell adhesion assays with a panel of cell lines and ligands designed to isolate adhesion mediated by individual integrin heterodimers (Fig. 1D, fig. S1, and table S1). The most promising compound, c8 (Fig. 1B), is one of two compounds predicted to have the highest affinity based on its excellent fit to the modeled integrin structure. Indeed, c8 inhibited αvβ1 integrin–mediated cell adhesion to the previously identified ligand fibronectin (8), with a sub-nanomolar median inhibitory concentration (IC50), but only minimally inhibited binding mediated by other related integrins up to concentrations five orders of magnitude higher (Fig. 1E and table S1). A related compound, c6, performed similarly well in binding assays (fig. S2). The remarkable specificity obtained for c8 and c6 demonstrated the effectiveness of our chimeric design strategy and provided us with novel reagents to examine αvβ1 integrin function.

Identification of widespread expression of the αvβ1 integrin on fibroblasts and a critical role for this integrin in activation of latent TGFβ by these cells

To determine the functional relevance of the αvβ1 integrin, we began by examining its possible role in the process of tissue fibrosis (12). Fibrosis is a critical contributor to many chronic diseases that eventually lead to organ failure. Despite the societal burden of fibrotic diseases, there are currently few approved therapies. As we reported for hepatic stellate cells, primary murine lung fibroblasts and human fetal and adult lung fibroblasts, as well as lung fibroblasts from patients with idiopathic pulmonary fibrosis (IPF), all clearly expressed the αvβ1 integrin as determined by immunoprecipitation (IP) of αv, followed by Western blotting for β1 (Fig. 2A and fig. S5). In contrast, whereas both the αv and β1 subunits were easily detectible in primary endothelial and epithelial cells, coimmunoprecipitation did not detect the αvβ1 heterodimer in these cells.

Fig. 2. αvβ1 is expressed on pulmonary and hepatic fibroblasts and mediates adhesion to TGFβ1 LAP and activation of latent TGFβ.

(A) Coimmunoprecipitation and Western blot reveal expression of αvβ1 heterodimers in human and murine cell lines from the liver and lung. Cell lysates were immunoprecipated with antibodies to αv (antibody RMV-7 for murine cells or L230 for all other cells), followed by Western blotting for either αv (lower panels, to control for capture, antibody 611012) or β1 (upper panels, antibody 04-1109). nhLu fb control (normal human lung fibroblasts from an uninjured control subject); IPF fb (lung fibroblasts isolated from a patient with IPF); mLu fb (murine lung fibroblasts); mHSC (murine hepatic stellate cells); WI38 (diploid human lung fibroblast); CHO [WT (wild-type)] control α5-deficient CHO cells (which lack expression of αvβ1); CHO (αv) (α5-deficient CHO cells engineered to express the αvβ1); hAT2 (human alveolar type 2 cells, which lack expression of αvβ1); hPAEC (human pulmonary artery endothelial cells, which lack expression of αvβ1). IgG, immunoglobulin G. (B) WT CHO cells (lacking αvβ1) adhere poorly, whereas CHO cells with forced expression of αvβ1 (CHO αv) and WI38 cells strongly adhere to TGFβ1 LAP. (C) WI38 cell adhesion to TGFβ1 LAP (0.3 μg/ml) is inhibited by c8 (IC50 = 0.72 nM). (D) c8 treatment reduced activation of TGFβ by cells expressing αvβ1 (IC50 range, 0.35 to 0.50 nM). Fibroblasts (as indicated) were cocultured with TGFβ reporter (PAI1-luciferase) cell line in the presence of a range of concentrations of c8. Data represent means ± SEM, n = 3 (three experimental replicates).

We and others have reported that the closely related αv integrins αvβ6 (9) and αvβ8 (11) can each bind to an N-terminal fragment of the TGFβ1 and TGFβ3 gene products called the LAP, which normally forms a noncovalent complex with the active cytokine, preventing TGFβ from binding to its receptors and inducing biological effects. When mechanical force is applied to the latent complex by contraction of integrin-expressing cells, the resultant conformational change leads to release of active TGFβ1 (21). Our previous work suggested that an αv integrin on fibroblasts contributed to tissue fibrosis by binding to and activating TGFβ (17). To determine whether the relevant fibroblast integrin could be αvβ1, we performed cell adhesion assays with either primary fibroblasts, control α5-deficient Chinese hamster ovary (CHO) cells or α5-deficient CHO cells engineered to express the αvβ1 integrin (8). Both fetal lung fibroblasts (WI38 cells) and αvβ1 integrin–expressing CHO (CHO αv) cells efficiently adhered to a range of concentrations of TGFβ1 LAP, whereas control CHO (CHO wild-type) cells did not (Fig. 2B and table S2). This adhesion could be inhibited by c8 with a similar IC50 as that shown for inhibition of adhesion to fibronectin (Fig. 2C and table S3). Adhesion to LAP could be inhibited by antibodies to either β1 or αv, but not with antibodies to either αvβ3, αvβ5, αvβ6, or αvβ8 (fig. S3). We used a coculture system to quantitatively assess TGFβ activation (22) and found that c8 potently and specifically inhibited activation of TGFβ by CHO cells engineered to express the αvβ1 integrin and by a variety of primary murine and human lung fibroblasts, including fibroblasts from the lungs of patients with IPF, and murine hepatic stellate cells (Fig. 2D and table S4). The IC50 for c8-mediated inhibition of TGFβ activation by these cells ranged from 0.35 to 0.50 nM, close to the IC50 of 0.75 nM for inhibition of WI38 cell adhesion to LAP (Fig. 2C). Together, these data suggest that αvβ1 is the principal integrin on fibroblasts responsible for adhesion to TGFβ1 LAP and for activation of latent TGFβ. A biochemical association between the αvβ1 integrin and TGFβ1 LAP was previously reported on the basis of affinity chromatography (23), but this is the first evidence that contractile cells can use this integrin to activate TGFβ.

In vivo role of the αvβ1 integrin in liver and lung fibrosis

Having established that c8 inhibits fibroblast adhesion to TGFβ1 LAP and TGFβ activation by fibroblasts from multiple organs, we used this inhibitor to examine the role of αvβ1 integrin–mediated TGFβ activation in two widely used models of pathologic tissue fibrosis: carbon tetrachloride (CCl4)–induced hepatic fibrosis and bleomycin-induced pulmonary fibrosis. To determine whether αvβ1 might be a promising therapeutic target, we waited until fibrosis was established in each model (21 days for CCl4 and 14 days for bleomycin) and then began continuous subcutaneous administration of either c8 or an inactive control compound, c16. In each model, c8 caused a substantial and significant reduction in fibrosis, as measured by either total area of collagen staining or total organ hydroxyproline content (a measure of cross-linked collagen) (Fig. 3, A to F, and tables S5 and S6). These results are highly comparable to the protection we previously reported in mice with conditional deletion of all αv integrins from activated fibroblasts (17), suggesting that αvβ1 was probably the major αv integrin responsible for that effect.

Fig. 3. c8 protects from liver and lung fibrosis.

(A) Effects of c8 or c16 on mouse fibrosis model (liver). c8 or c16 (inactive control compound) was continuously delivered by Alzet pump beginning 3 weeks after intraperitoneal administration with oil (sham) or CCl4 to induce liver fibrosis. (B and C) Treatment with c8 significantly reduced liver fibrosis, as determined by (B) Sirius red staining (collagen deposition) of liver tissue after olive oil (top panels) or CCl4 treatment (bottom panels), (C) digital image analysis quantification of collagen staining, and hydroxyproline analysis. Sirius red (liver) n = 8; P = 0.0005. Hydroxyproline (liver) n = 10; P < 0.0001. (D) Effects of c8 or c16 on murine fibrosis model (lung). c8 or c16 was continuously delivered to mice using Alzet pumps beginning 14 days after intratracheal instillation of bleomycin (Bleo) to induce pulmonary fibrosis or water (H2O). (E and F) Treatment with c8 significantly reduced lung fibrosis, as determined by (E) Sirius red staining (collagen deposition) of lung tissue after water (top panels) or bleomycin treatment (bottom panels), (F) digital image analysis quantification of collagen staining, and hydroxyproline analysis. Sirius red (lung) n = 10; P = 0.0022. Hydroxyproline (lung) n = 10; P = 0.0027. Data represent means ± SEM. Scale bars, 100 μm. P values were calculated using the unpaired Student’s t tests.

Likewise, phosphorylated Smad3 (pSmad3) fluorescence intensity mapping revealed significant down-regulation of canonical (Smad-mediated) TGFβ signaling (Fig. 4), suggesting that antifibrotic effects of c8 are due to inhibition of αvβ1 integrin–mediated TGFβ activation in vivo.

Fig. 4. Reduced pSmad3 in mice treated with c8.

(A) Representative liver (top panels) and lung (bottom panels) sections from mice treated with c16 or c8 after induced fibrotic injury stained for fibroblasts [PDGFRβ (platelet-derived growth factor receptor β), green] and pSmad3 (red). (B) Quantification of pSmad3 nuclear intensity within individual PDGFRβ+ cells documents a significant reduction in fibroblast-specific pSmad3 in fibrotic mice treated with c8. Data represent means ± SEM; n = 102 (Bleo c8), n = 254 (Bleo c16), n = 262 (CCl4 c8), and n = 361(CCl4 c16). For both comparisons, P < 0.0001 (shown is a representative example of the distribution of individual pSmad3 mean fluorescence intensities in PDGFRβ+ cells, and the average of these means, for a single sample condition). Scale bar, 100 μm. P values were calculated using the unpaired Student’s t tests.


Here, we used a structure-based design to generate the first highly potent and specific inhibitor of the αvβ1 integrin. Our results demonstrating a difference of more than five orders of magnitude between concentrations of this inhibitor required to inhibit αvβ1 compared to six other integrins that all recognize ligands containing the same arginine–glycine–aspartic acid tripeptide suggest that this reagent is highly selective and should be broadly useful in identifying specific functional roles for αvβ1 in vitro and in vivo. Our finding that αvβ1 is the major integrin on several different primary fibroblasts responsible for binding to TGFβ1 LAP and for mediating activation of latent TGFβ by these cells clarifies several previous reports of integrin-mediated TGFβ activation by contractile fibroblasts (17, 24). Our findings that this αvβ1-specific small-molecule inhibitor results in the same degree of reversal of liver and lung fibrosis as we previously reported for deletion of all αv integrins from fibroblasts provide the first convincing evidence that the αvβ1 integrin is the major integrin on pathologic fibroblasts responsible for activating latent TGFβ and driving tissue fibrosis in multiple organs. Previous studies have identified expression of αvβ1 on a variety of immortalized cell lines, including A549 (23) and human embryonic kidney cells (293 cells) (25), but the ligand or ligands recognized by this integrin have been controversial, and the functional significance of αvβ1 has been difficult to determine in the absence of effective and specific inhibitors. αvβ1 has thus been alternately described as a receptor for vitronectin (25), fibronectin (8), and the adenovirus penton base (26). One previous study used affinity chromatography of surface-labeled lysates of A549 cells passed over a column composed of recombinant TGFβ1 LAP cross-linked to Sepharose beads and found that αvβ1 could bind to TGFβ1 LAP, but despite performing coculture TGFβ activity bioassays like the one we used here, the authors could not demonstrate evidence of TGFβ activation (23).

Recent work overexpressing integrin subunits and latent TGFβ in 293 cells also did not demonstrate evidence of TGFβ activation by αvβ1 (27). To try to understand the apparent differences between our results and these previous reports, we performed cell adhesion assays and coculture TGFβ bioassays with A549 and 293 cells using the same methods and reagents we used to study CHO cells and fibroblasts (fig. S4). We confirmed that A549 cells adhere well to TGFβ1 LAP and also found evidence of TGFβ activation. Both effects were potently inhibited by concentrations of c8 as low as 1 nM. However, despite confirming that 293 cells express αvβ1, we did not find meaningful adhesion to TGFβ1 LAP or TGFβ activation by these cells. Future studies examining why 293 cells are incapable of activating TGFβ using this integrin could provide insight into additional mechanisms of regulation of integrin-mediated TGFβ activation.

An important limitation of the current study is that we did not definitively prove that inhibition of TGFβ activation is the only mechanism by which inhibition of αvβ1 decreases the magnitude of tissue fibrosis. Although our data suggest that TGFβ activation is one important function of αvβ1, it certainly remains possible that other as yet unidentified functions of this integrin also have important effects on tissue fibrosis. The mechanisms that regulate formation and surface expression of the αvβ1 heterodimer also need to be identified, because both αv and β1 monomers are expressed in nearly every cell, but only a minority of cells ever express the αvβ1 heterodimer on their surface. Finally, our finding that 293 cells can express αvβ1 but are incapable of either binding to TGFβ1 LAP or activating latent TGFβ suggests that there are additional positive and/or negative regulators of the interaction between αvβ1 and TGFβ that remain to be identified.

The significant therapeutic effect of our small-molecule αvβ1 integrin inhibitor in two different models of fibrotic disease suggest that this integrin could be a promising target for treatment of the multiple chronic diseases characterized by excessive tissue fibrosis. c8 also should be a useful tool to identify additional roles for this understudied member of the integrin family in modulating cell behavior and in vivo biology.


Study design

The overall goals of this study were to develop and characterize a small-molecule inhibitor of the αvβ1 integrin and to assess the possibility that this integrin might be a reasonable therapeutic target for fibrotic diseases affecting multiple organs. To assess the potency and specificity of the candidate inhibitors that we developed, we used in vitro cell adhesion assays and TGFβ activation assays. All in vitro experiments were done at least three times with at least triplicate samples.

To evaluate the potential efficacy of our lead small-molecule c8 in vivo, we compared the effects of c8 to those of the inactive peptide analog c16 in mice treated either with vehicle alone or with the fibrogenic stimuli bleomycin (for induction of pulmonary fibrosis) or CCl4 (for induction of liver fibrosis). Sample size was selected on the basis of extensive experience with each model to allow us to reliably detect a 50% reduction in the magnitude of fibrosis. Treatments were all delivered by continuous subcutaneous infusion beginning at a time point at which we and others had previously demonstrated that fibrosis was already present. Mice were randomized for inclusion in each of the four treatment arms, and all analyses were performed blind to inciting stimulus and treatment. All surviving mice were included for analysis.

Synthesis of inhibitors

Preparation of (PhSO2)Pro-(pNO2)Phe-OtBu. Diisopropylethylamine (DIPEA) (1 eq), hydroxybenzotriazole (HOBt) (1 eq), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC•HCl) (1 eq) were added to benzenesulfonylproline (40 mmol) in anhydrous dichloromethane (DCM) (100 ml) at 0 °C, and the solution was stirred for 1 min. Then, nitrophenylalanine t-butylester in DCM (300 ml) was added at the same temperature and warmed to room temperature (rt) and stirred overnight. The reaction mixture was washed with 1 N hydrochloric acid (HCl), 10% sodium bicarbonate (NaHCO3), and brine successively. The volatiles were removed under reduced pressure, and the crude product was used without further purification (yellowish foam, 70%). 1H NMR (nuclear magnetic resonance) [dimethylsulfoxide (DMSO)–d6, 300 MHz] δ ppm 8.4 (1H, s), 8.25 (2H, br s), 7.81-7.57 (7H, m), 4.49 (1H, s), 4.09 (1H, s), 3.34-3.12 (5H, m), 1.58 (3H, br s), and 1.38 (9H, s); LRMS (low-resolution mass spectrometry) [ESI+ (positive electrospray ionization)] 526.4 (MNa+).

Preparation of (PhSO2)Pro-(pNH2)Phe-OtBu. A slurry of Pd/C (palladium on carbon) (0.1 eq based on weight) in MeOH (methanol)/H2O (1:1, 10 ml) and ammonium formate (9 eq) were added to a solution of the above nitrobenzene (27.9 mmol) in MeOH/THF (tetrahydrofuran) (1:1, 300 ml) at rt. The mixture was heated at 60 °C for 3 hours and cooled to rt. The mixture was filtered through a pad of Celite and concentrated. The crude residue was dissolved in ethyl acetate and washed with saturated NaHCO3 solution, dried over sodium sulfate (Na2SO4), and concentrated under reduced pressure. The crude product was used without further purification (off-white foam, 70%). 1H NMR (CDCl3, 300 MHz) δ ppm 7.82 (1H, d, J = 9.6 Hz), 7.62-7.53 (3H, m), 7.26-7.22 (1H, m), 6.92 (1H, d, J = 10.7 Hz), 6.57 (1H, d, J = 10.8Hz), 4.65-4.54 (1H, m), 4.2-4.05 (1H, m), 3.7-3.3 (m, 2H), 3.2-3.0 (2H, m), 2.95-2.85 (1H, m), 2.05 (1H, br s), and 1.6-1.3 (11H, br s); LRMS (ESI+) 496.2 (MNa+), 474.5 (MH+).

Preparation of (PhSO2)Pro-(pNHCOCH2CH2CH2CH2NHC= NBocNHBoc)Phe-OtBu. DIPEA (1 eq), HOBt (1 eq), and EDC•HCl (1 eq) were added to the bis-Boc–protected aminopentanoic acid (11.2 mmol) (28) in anhydrous DCM (80 ml) at 0 °C, and then the amine from the previous step (1 eq) in DCM (20 ml) was added at the same temperature, warmed to rt, and stirred overnight. The reaction mixture was washed with 1 N HCl, 10% NaHCO3, and brine successively. The solvent was removed under reduced pressure and purified by silica gel column chromatography (DCM/MeOH, 2% to 5%) to give the off-white foam (74%).

Preparation of c8. The bis-Boc–protected compound prepared from the previous step (8.3 mmol) was treated with 5% anisole in trifluoroacetic acid (TFA) (30 ml) for 3 hours at rt. The volatiles were removed under reduced pressure, and the crude product was washed with diethyl ether several times. The TFA salt was exchanged to chloride using 4 M HCl in dioxane and evaporation under reduced pressure (three times). The final salt was passed through a short pad of silica and dried under reduced pressure. 1H NMR (TFA salt) (300 MHz, DMSO-d6) ppm δ 9.86 (s, 1H), 8.12 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 6.9 Hz, 2H), 7.70 (d, J = 7.2 Hz, 1H), 7.62–7.15 (m, 7H), 4.41 (s, 1H), 4.15 (s, 1H), 3.33 (s, 1H), 3.1–2.92 (m, 5H), 2.3 (s, 2H), and 1.59–1.48 (m, 8H); LRMS (ESI+) 559 (MH+).


Wild-type C57BL/6 mice were purchased from Jackson Laboratories. Eight- to 12-week-old sex-matched mice were housed under specific pathogen–free conditions in the Animal Barrier Facility of the University of California, San Francisco (UCSF). All experiments were approved by the Institutional Animal Care and Use Committee of the UCSF.

Fibrosis models

Lung and liver fibrosis were induced as described previously (17). In all studies, mice were randomly assigned for each treatment and analyzed in a blinded fashion. For CCl4-induced liver fibrosis, mice were injected intraperitoneally with sterile CCl4 (1 μl/g body weight) in a 1:3 ratio with olive oil or olive oil (sham), twice weekly for 6 weeks. Alzet osmotic pumps (Durect) were inserted after 3 weeks of treatment to deliver either c8 or the inactive control small-molecule c16, each dissolved in 50% DMSO (in sterile water) and administered at a dose of 70 mg/kg per day. Livers were harvested 24 hours after the last CCl4 injection. For bleomycin-induced lung fibrosis, bleomycin (3 U/kg) (Bleo) or water (control) was administered by direct airway intubation with a microsprayer (Penn-Century Inc.). Alzet osmotic pumps were inserted 14 days after treatment as above, and lungs were harvested at 28 days.

Primary cell isolation

Primary murine lung fibroblasts were isolated from 4- to 12-day-old mice using a previously reported method with minor modifications (29). Mouse lungs were removed, pooled together, and digested in an enzyme solution [Hanks’ balanced salt solution (without Ca or Mg) with type I collagenase (0.3 mg/ml) (Sigma) and trypsin (0.5 mg/ml) (Sigma)] for 1 hour with removal of dispersed cells every 10 min. Dispersed cells were passed through a sterile filter (70 μm) into Dulbecco’s modified Eagle’s medium (DMEM)–Ham’s F-12 medium (Sigma) and 10% fetal bovine serum, and undigested lung tissue was placed in fresh enzyme solution. Once digestion was complete, erythrocytes were lysed at rt for 10 min using red blood cell lysing buffer (Sigma). Cells were pelleted by centrifugation and cultured in DMEM with 10% fetal bovine serum and 1% penicillin/streptomycin. Nonadherent cells were aspirated and discarded. Primary murine hepatic stellate cells were isolated and passaged as described previously (17). Mouse liver was perfused through the inferior vena cava sequentially with liver perfusion medium (Invitrogen), 0.3% pronase (Roche), and 0.02% collagenase (Sigma). The liver was excised and minced with scissors and further digested in 0.044% pronase and 0.008% deoxyribonuclease (DNase) (Roche). The cell suspension was shaken (200 to 250 rpm) at 37 °C for 10 min and strained through a sterile filter (70 μm). To remove hepatocytes, the cell suspension was centrifuged at 90g for 2 min, the supernatant was collected, and DNase was added; this procedure was repeated twice. The supernatant was centrifuged at 700g for 7 min to collect the nonparenchymal cell fraction. Collected cells were resuspended in 10 ml of complete DMEM with 10% fetal bovine serum and 1% penicillin/streptomycin and allowed to differentiate in culture into myofibroblasts before use.

Hydroxyproline assay

Mouse lung and liver tissues were homogenized with trichloroacetic acid and incubated overnight at 110 °C in HCl. Samples were reconstituted in water, and hydroxyproline content was measured using the chloramine T assay (30).

IP and Western blotting

Cells were lysed in radioimmunoprecipitation assay buffer [50 mM tris-HCl (pH 7.4), 10 mM MgCl2, 125 mM NaCl, and 2% NP-40]. Cell lysates were centrifuged at 14,000 rpm for 10 min at 4 °C, and the supernatant was collected. Anti-αv antibody (20 μg) was added to the supernatant, and this was rotated at 4°C for 2 hours, followed by the addition of 30 μl of prewashed protein G–Sepharose slurry (GE Healthcare) for 1 hour at 4 °C. The beads were washed three times with phosphate-buffered saline (PBS)/protease inhibitor mixture and once with PBS only. Laemmli sample buffer was added, the samples were boiled for 5 min followed by SDS–polyacrylamide gel electrophoresis, and Western blotting was performed. The antibodies that we used for αv IP were RMV-7 for murine cell lines and L230 for all other cell lines. For αv Western blotting, we used 611012 (1:500) (BD Biosciences), and for β1 Western blotting, we used 04-1109 (1:500) (Millipore).

TGFβ activation assay

Test cells were plated at 50,000 cells per well in 96-well plates together with mink lung epithelial cells expressing firefly luciferase downstream of the TGFβ-sensitive portion of the plasminogen activator inhibitor 1 promoter (15,000 to 25,000 cells per well) (22). Cells were cocultured for 16 hours, and TGFβ activity was calculated by measurement of luminescence in the presence and absence of TGFβ-blocking antibody 1D11.

Integrin-specific adhesion assays

The effects of c8 and c16 on cell adhesion mediated by α5β1, α8β1, αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8 were measured using pairs of cell lines and ligands selected to isolate the effect of each individual integrin. For α5β1, we used the colon carcinoma cell line SW480 plated on fibronectin (0.3 μg/ml); for α8β1, we used SW480 cells transfected with human α8 adhering to recombinant human TGFβ1 LAP (1 μg/ml) (31); for αvβ1, we used CHO αv5-deficient CHO cells engineered to express αvβ1) adhering to fibronectin (0.3 μg/ml) (8); for αvβ3, we used SW480 cells transfected with human β3 adhering to fibrinogen (1 μg/ml); for αvβ5, we used wild-type SW480 cells adhering to vitronectin (0.1 μg/ml); for αvβ6, we used SW480 cells transfected with human β6 adhering to recombinant human TGFβ1 LAP (0.01 μg/ml); and for αvβ8, we used the glioma cell line (SNB19) adhering to recombinant human TGFβ1 LAP (1 μg/ml). In every case, we confirmed that adhesion could be inhibited by blocking antibodies to the relevant integrin (complex-specific blocking antibodies in all cases except αvβ1 for which we showed equivalent effects of blocking αv). Cells were resuspended in DMEM for 15 to 30 min at 4°C with 10-fold dilutions of c8 with a starting concentration of 10 μM. Each sample was then added to triplicate wells of a 96-well plate that had been coated overnight at 4°C with the relevant ligand, washed with PBS, blocked by 1-hour incubation with 1% bovine serum albumin (BSA), and washed again. Cells were allowed to attach for 60 min at 37°C. After incubation, nonadherent cells were removed by discarding the medium and spinning the plate topside down at 500 rpm for 5 min. Cells were then fixed and stained with 40 μl of 0.5% crystal violet, 1% formaldehyde, 20% MeOH in double-distilled water for 30 min and lysed with 40 μl of 2% Triton-X in PBS. Absorbance was measured at 595 nm in a microplate reader. For all assays, concentration-response curves were constructed by nonlinear regression analysis, and IC50 values were calculated using GraphPad Prism software.

Tissue staining

Paraffin-embedded sections were processed as described previously (17). Sections (5 μm) were stained with hematoxylin and eosin or with Sirius red. Pictures were taken from random fields from each section at a final magnification of ×10. Staining area was calculated by pixel counting with National Institutes of Health (NIH) ImageJ. For fluorescence microscopy, fixed livers and lungs were transferred to 30% sucrose in PBS overnight, embedded in optimum cutting temperature compound, and then cryosectioned at 5 μm. Cryosections were permeabilized and blocked with 0.3% Triton X-100 and 3% BSA in PBS. Sections were incubated with primary antibodies (rabbit anti-pSmad3, Epitomics, 1880-1, 1:100; rat anti-PDGFRβ, eBioscience, 14-1402, 1:100) overnight at 4 °C and then with fluorophore-conjugated secondary antibodies (Invitrogen). Confocal imaging was performed on a Zeiss LSM 5 Pascal microscope. pSmad immunofluorescence staining was quantified as described (32).

Statistical analysis

All results are presented as means ± SEM. Exact P values were calculated using the unpaired Student’s t test for normally distributed data using GraphPad Prism 6.0. P values and n numbers are shown in the figure legends.


Fig. S1. Validation of cell adhesion conditions used to determine potency and specificity of αvβ1 inhibitors.

Fig. S2. C8 and C6 adhesion assays.

Fig. S3. Adhesion of WI38 cells in low concentration of TGFβ1 LAP.

Fig. S4. Adhesion and TGFβ activation assays in A549 and 293 cells.

Fig. S5. Original Western blot images of Fig. 2A.

Table S1. Source data for Fig. 1 (D and E).

Table S2. Source data for Fig. 2B.

Table S3. Source data for Fig. 2C.

Table S4. Source data for Fig. 2D.

Table S5. Source data for Fig. 3C.

Table S6. Source data for Fig. 3F.


Acknowledgments: We thank E. Wright (University of Michigan) for providing primary human fibroblast from normal lungs and lungs of patients with IPF. We thank R. Juliano (University of North Carolina) for providing integrin α5–deficient CHO cells. We thank Y. Yokosaki (Hiroshima University) for providing chicken anti-α8β1 antibody. We thank L. Schnapp (University of South Carolina) for providing SW480 cells transfected with human integrin α8. We thank H. Yagita (Juntendo University) for providing anti-αv antibody RMV-7. We thank S. Sen from the UCSF Department of Epidemiology and Biostatistics for expert consultation on study design and statistical analysis. Funding: Financial support was provided by the U.S. NIH grants HL53949 (D.S.), HL108794 (D.S.), and the UCSF Program for Breakthrough Biomedical Research, funded in part by the Sandler Foundation (W.F.D. and D.S.). Author contributions: N.I.R., H.J., D.S., and W.F.D. designed the experiments and analyzed the data. N.I.R. performed in vitro adhesion assays and in vivo fibrosis experiments. W.F.D. and H.J. designed and synthesized the inhibitors. C.C., N.I.R., and K.T. determined cellular expression of αvβ1. N.I.R. and T.D.A. performed studies of in vivo TGFβ activation. D.S. and W.F.D. directed the studies. N.I.R., H.J., T.D.A., D.S., and W.F.D. wrote the manuscript, and all authors reviewed it. Competing interests: N.I.R., H.J., D.S., and W.F.D. are the inventors of the U.S. Patent application no. 61/884,583 related to this work. Data and materials availability: c8 can be available for research purposes through a material transfer agreement with UCSF.
View Abstract

Navigate This Article